Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV

被引：6

作者：

Vaccari, Monica ^{[1
]}

Poonam, Poonam ^{[1
]}

Franchini, Genoveffa ^{[1
]}

机构：

[1] NCI, Anim Models & Retroviral Vaccine Sect, NIH, Bethesda, MD 20892 USA

来源：

EXPERT REVIEW OF VACCINES | 2010年 / 9卷 / 09期

关键词：

gp120; HIV; neutralizing antibodies; Phase III; prime-boost; T-cell responses; vaccine trial; T-LYMPHOCYTE RESPONSES; IMMUNODEFICIENCY-VIRUS SIV; RECOMBINANT CANARYPOX; SIMIAN-IMMUNODEFICIENCY; ALVAC-HIV; IMMUNE-RESPONSES; POXVIRUS VECTORS; TYPE-1; VACCINE; DOUBLE-BLIND; GP120;

D O I：

10.1586/ERV.10.104

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The large human efficacy trail in Thailand, RV144, was concluded in the summer of 2009. This is the first Phase III trial to show limited, but significant, efficacy in preventing HIV acquisition. This trial represents the first sign that a preventive vaccine for HIV may be feasible. The vaccine regimen tested in Thailand consisted of priming with a Canarypox vector carrying three synthetic HIV genes. The priming was followed by booster inoculations with two recombinant envelope proteins from HIV, clade B and E. The need to understand the role in protection from HIV acquisition of the new responses, induced by this vaccine combination, has brought together many researchers with the common goal of improving the development of a safe and effective vaccine for HIV.

引用

页码：997 / 1005

页数：9

共 77 条

[21]

EXCLER JL, 1997, AIDS SA, V11, P10

[22]

Flynn MN, 2005, J INFECT DIS, V191, P654, DOI 10.1086/428404

[23] Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I [J].

Franchini, G ;

Benson, J ;

Gallo, R ;

Paoletti, E ;

Tartaglia, J .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (05) :407-408

[24] HIGHLY ATTENUATED HIV TYPE-2 RECOMBINANT POXVIRUSES, BUT NOT HIV-2 RECOMBINANT SALMONELLA VACCINES, INDUCE LONG-LASTING PROTECTION IN RHESUS MACAQUES [J].

FRANCHINI, G ;

ROBERTGUROFF, M ;

TARTAGLIA, J ;

AGGARWAL, A ;

ABIMIKU, A ;

BENSON, J ;

MARKHAM, P ;

LIMBACH, K ;

HURTEAU, G ;

FULLEN, J ;

ALDRICH, K ;

MILLER, N ;

SADOFF, J ;

PAOLETTI, E ;

GALLO, RC .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (08) :909-920

[25]

Franchini Genoveffa, 2004, Expert Rev Vaccines, V3, pS75, DOI 10.1586/14760584.3.4.S75

[26]

Francis D P, 2001, AIDS Alert, V16, P141

[27]

Francis DP, 1998, AIDS RES HUM RETROV, V14, pS325

[28] Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide-vaccine:: Characterization of CD8+-T-cell epitopes recognized [J].

Gahéry-Ségard, H ;

Pialoux, G ;

Figueiredo, S ;

Igéa, C ;

Surenaud, M ;

Gaston, J ;

Gras-Masse, H ;

Lévy, JP ;

Guillet, JG .

JOURNAL OF VIROLOGY, 2003, 77 (20) :11220-11231

[29] Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus [J].

Girard, M ;

vanderRyst, E ;

BarreSinoussi, F ;

Nara, P ;

Tartaglia, J ;

Paoletti, E ;

Blondeau, C ;

Jennings, M ;

Verrier, F ;

Meignier, B ;

Fultz, PN .

VIROLOGY, 1997, 232 (01) :98-104

[30] HIV type 1 vaccine-induced T cell memory and cytotoxic T lymphocyte responses in HIV type 1-uninfected volunteers [J].

Gorse, GJ ;

Patel, GB ;

Belshe, RB .

AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (12) :1175-1189

← 1 2 3 4 5 6 7 8 →